Blog

The findings could inform the development of a vaccine that could eliminate the need for daily HIV medication.

While a vaccine will represent a significant turning point in the fight against COVID-19, there will still be a long way to go.

CAR T cell therapy is a promising form of treatment for cancer, and now Ragon Institute investigator Todd Allen, PhD, recently published findings suggesting dual CAR T cell therapy could be an option for HIV.

Recent research from Ragon Institute researcher Xu Yu, MD, finds that HIV elite controllers can prevent the virus from replicating by sequestering the viral genome in gene deserts.

In a guest blog post, Mass General and Ragon Institute researcher Shiv Pillai, MD, PhD, explains his research examining why COVID-19 immunity may be challenging: The virus could be causing immune system amnesia.

At a recent virtual town hall led by Bruce Walker, MD, researchers discussed what they have learned so far about COVID-19 antibodies and their vision for how to return to work.

Investigators at the Ragon Institute of MGH, MIT and Harvard have identified a key weakness in the HIV virus thanks in part to flexible funding provided by philanthropy.

To understand more about infant immunity and how to enhance it, a research team led by Galit Alter, PhD investigated how certain antibodies are transferred from mother to child during pregnancy.

In recognition of World AIDS Day, we are sharing some recent work from the Ragon Institute of MGH, MIT and Harvard, which was established in 2009 with a dual mission to contribute to the accelerated discovery of an HIV/AIDS vaccine and to serve as a world leader in the collaborative study of immunology.

Researchers at the Ragon Institute of Massachusetts General Hospital, MIT and Harvard recently published an editorial in Science Immunology detailing their efforts to combine basic science and social good to reduce the high rate of HIV infection in young South African women while simultaneously empowering them. Here is a brief summary.